• 1四川省樂山市市中區(qū)人民醫(yī)院心內(nèi)科,四川樂山 614000; 2首都醫(yī)科大學(xué)附屬北京安貞醫(yī)院心內(nèi)科, 北京 100029;

目的:觀察血清C-反應(yīng)蛋白(CRP) 水平與急性心肌梗死(AMI)患者6個月時心功能及病死率的關(guān)系。方法:入選我院572例AMI住院患者,根據(jù)入院時CRP水平分為CRP升高組及CRP正常組,隨訪6個月,記錄超聲心動圖結(jié)果及死亡例數(shù)。結(jié)果:兩組基線資料無明顯差異。與入院時CRP正常組比較,CRP升高組患者6個月時LVEDD、LVESD,住院期間及隨訪期間病死率顯著增加,而6個月時LVEF顯著降低 (P  lt; 0.05)。多因素分析結(jié)果顯示入院時CRP升高是AMI患者住院期間及6個月病死率的獨立危險因素。結(jié)論:血清CRP升高是AMI患者心功能及病死率的預(yù)測因素,關(guān)注AMI患者血清CRP水平,盡早開始控制,有利于改善AMI的預(yù)后。

引用本文： 尹黎波,王春梅. 血清C反應(yīng)蛋白對急性心肌梗死的預(yù)后價值. 華西醫(yī)學(xué), 2009, 24(8): 2003-2005. doi: 復(fù)制

1. RIDKER P M. Highsensitivity Creactive protein: potential adjunct for global risk assessmention the primary prevention of cardiovascular disease[J].Circulation, 2001, 103: 1813-1818.
2. RIDKER P M, RIFAI N, STAMPFER M J, et al. Plasma concentration of interleukin6 and the risk of future myocardial infarction among apparently healthymen[J]. Circulation, 2000, 101: 1767-1772.
3. PEARSON T A, MENSAH G, ALEXANDER R W,et al. Markers of inflammation and cardiovascular disease;Application to clinical and public health practice: a statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association[J]. Circulation, 2003,107:499.
4. RIDKER P M, STAMPFER M J, RIFAI N. Novel risk factors for systemic atherosclerosis: a comparison of Creactive protein fibrinogen, homocysteine, lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease[J].JAMA, 2001,285:2481.
5. LIBBY P, RIDKER P M, MASERI A. Inflammation and atherosclerosis[J]. Circulation, 2002,105: 1135.
6. SAKKINEN P, ABBOTT R D, CURB J D, et al. Creactive protein and myocardial infarction[ J ]. J Clin Epidemiol, 2002, 55 (5): 445-451.
7. MUELLER C, BUETTNER H J, HODGSON J M. Inflammation and Longterm mortality after nonSTelevation acute coronary syndrome treated with a very early invasive strategy in 1 042 consecutive patients[J].Circulation,2002,105:1412.
8. ALMAGOR M, KEREN A, BANAI S. Increased C reactive protein level after coronary stent implantation in patients with stable coronary artery disease[J].Am Heart J,2003,145(2):248.
  1. 1. RIDKER P M. Highsensitivity Creactive protein: potential adjunct for global risk assessmention the primary prevention of cardiovascular disease[J].Circulation, 2001, 103: 1813-1818.
  2. 2. RIDKER P M, RIFAI N, STAMPFER M J, et al. Plasma concentration of interleukin6 and the risk of future myocardial infarction among apparently healthymen[J]. Circulation, 2000, 101: 1767-1772.
  3. 3. PEARSON T A, MENSAH G, ALEXANDER R W,et al. Markers of inflammation and cardiovascular disease;Application to clinical and public health practice: a statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association[J]. Circulation, 2003,107:499.
  4. 4. RIDKER P M, STAMPFER M J, RIFAI N. Novel risk factors for systemic atherosclerosis: a comparison of Creactive protein fibrinogen, homocysteine, lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease[J].JAMA, 2001,285:2481.
  5. 5. LIBBY P, RIDKER P M, MASERI A. Inflammation and atherosclerosis[J]. Circulation, 2002,105: 1135.
  6. 6. SAKKINEN P, ABBOTT R D, CURB J D, et al. Creactive protein and myocardial infarction[ J ]. J Clin Epidemiol, 2002, 55 (5): 445-451.
  7. 7. MUELLER C, BUETTNER H J, HODGSON J M. Inflammation and Longterm mortality after nonSTelevation acute coronary syndrome treated with a very early invasive strategy in 1 042 consecutive patients[J].Circulation,2002,105:1412.
  8. 8. ALMAGOR M, KEREN A, BANAI S. Increased C reactive protein level after coronary stent implantation in patients with stable coronary artery disease[J].Am Heart J,2003,145(2):248.